

# Piero L Olliaro

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7863744/piero-l-olliaro-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126  
papers

4,899  
citations

35  
h-index

68  
g-index

137  
ext. papers

6,717  
ext. citations

9  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
126	A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever.. <i>PLoS Neglected Tropical Diseases</i> , <b>2022</b> , 16, e0010089	4.8	0
125	Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development.. <i>BMC Medicine</i> , <b>2022</b> , 20, 50	11.4	11
124	Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.. <i>PLoS Neglected Tropical Diseases</i> , <b>2022</b> , 16, e0010289	4.8	1
123	Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study.. <i>ERJ Open Research</i> , <b>2022</b> , 8,	3.5	8
122	Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol.. <i>Wellcome Open Research</i> , <b>2021</b> , 6, 207	4.8	
121	Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: an observational cohort. <i>ELife</i> , <b>2021</b> , 10,	8.9	4
120	Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009302	4.8	3
119	Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009204	4.8	4
118	Remote-Controlled and Pulse Pressure-Guided Fluid Treatment for Adult Patients with Viral Hemorrhagic Fevers. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2021</b> ,	3.2	1
117	COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. <i>Lancet Microbe, The</i> , <b>2021</b> , 2, e279-e280	22.2	73
116	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine, the</i> , <b>2021</b> , 9, 349-359	35.1	70
115	Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 601-602	25.5	33
114	COVID-19 vaccines: effectiveness and number needed to treat - AuthorsReply. <i>Lancet Microbe, The</i> , <b>2021</b> , 2, e282	22.2	2
113	Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. <i>Trials</i> , <b>2021</b> , 22, 370	2.8	0
112	Managing the risks of making the wrong diagnosis: First, do no harm. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 106, 382-385	10.5	3
111	Evaluating clinical characteristics studies produced early in the Covid-19 pandemic: A systematic review. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251250	3.7	1
110	Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes. <i>ELife</i> , <b>2021</b> , 10,	8.9	1

109	What does 95% COVID-19 vaccine efficacy really mean?. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 769	25.5	15
108	Target product profile for a dengue pre-vaccination screening test. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009557	4.8	2
107	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet, The</i> , <b>2021</b> , 398, 223-237	40	39
106	Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	60
105	Time to reconsider the role of ribavirin in Lassa fever. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009528	4.8	3
104	Neglected tropical diseases in non-endemic countries in the era of COVID-19 pandemic: the great forgotten. <i>Journal of Travel Medicine</i> , <b>2021</b> , 28,	12.9	7
103	An integrated understanding of long-term sequelae after acute COVID-19. <i>Lancet Respiratory Medicine, the</i> , <b>2021</b> , 9, 679-680	35.1	3
102	Rolling out COVID-19 antigen rapid diagnostic tests: the time is now. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 1052-1053	25.5	14
101	SARS-CoV-2 rapid antigen detection tests - Authors Reply. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 1069-1070	2.5	2
100	Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009650	4.8	1
99	Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. <i>Clinical and Experimental Allergy</i> , <b>2021</b> , 51, 1107-1120	4.1	26
98	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. <i>Lancet Regional Health - Europe, The</i> , <b>2021</b> , 8, 100186		43
97	Scaling up COVID-19 rapid antigen tests: promises and challenges. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, e290-e295	25.5	97
96	Characterising long COVID: a living systematic review. <i>BMJ Global Health</i> , <b>2021</b> , 6,	6.6	78
95	Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009788	4.8	3
94	Cross-sectional study on intestinal parasite infections in different ecological zones of the Department of La Paz, Bolivia. <i>One Health</i> , <b>2021</b> , 13, 100271	7.6	
93	Treatment of Pregnant Women with Ivermectin during Mass Drug Distribution: Time to Investigate Its Safety and Potential Benefits.. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	1
92	The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): A case study of bubonic plague.. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0010064	4.8	0

91	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <i>Thorax</i> , <b>2021</b> ,	7.3	4
90	Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008277	4.8	5
89	Patients' preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0007996	4.8	3
88	Psycho-social impacts, experiences and perspectives of patients with Cutaneous Leishmaniasis regarding treatment options and case management: An exploratory qualitative study in Tunisia. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242494	3.7	3
87	Decline in Total Serum IgE and Soluble CD30 in the Context of Soil-Transmitted Helminth Decline in Bolivia. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2020</b> , 102, 847-850	3.2	1
86	Legal Uncertainty-The Gray Area around Substandard Medicines: Where Public Health Meets Law. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2020</b> , 102, 262-267	3.2	2
85	Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. <i>Journal of Travel Medicine</i> , <b>2020</b> , 27,	12.9	8
84	Sensitivity of C-reactive protein for the identification of patients with laboratory-confirmed bacterial infections in northern Tanzania. <i>Tropical Medicine and International Health</i> , <b>2020</b> , 25, 291-300	2.3	3
83	The time to do serosurveys for COVID-19 is now. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 836-838	35.1	9
82	An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial. <i>Trials</i> , <b>2020</b> , 21, 722	2.8	4
81	Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. <i>BMJ, The</i> , <b>2020</b> , 370, m3249	5.9	259
80	Towards harmonization of microscopy methods for malaria clinical research studies. <i>Malaria Journal</i> , <b>2020</b> , 19, 324	3.6	7
79	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. <i>BMJ, The</i> , <b>2020</b> , 370, m3339	5.9	378
78	What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review. <i>F1000Research</i> , <b>2020</b> , 9, 1455	3.6	1
77	Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis <b>2020</b> , 14, e0008277		
76	Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis <b>2020</b> , 14, e0008277		
75	Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis <b>2020</b> , 14, e0008277		
74	Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis <b>2020</b> , 14, e0008277		

73	The diagnosis and treatment of urogenital schistosomiasis in Italy in a retrospective cohort of immigrants from Sub-Saharan Africa. <i>Infection</i> , <b>2019</b> , 47, 447-459	5.8	8
72	Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002850	11.6	4
71	Breast Tuberculosis in Women: A Systematic Review. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2019</b> , 101, 12-21	3.2	5
70	Epidemic preparedness: why is there a need to accelerate the development of diagnostics?. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, e172-e178	25.5	16
69	Initiation and publication time-lags of treatment trials for Ebola virus disease. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, 28-29	25.5	3
68	Regulatory and Operational Complexities of Conducting a Clinical Treatment Trial During an Ebola Virus Disease Epidemic. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1454-1457	11.6	11
67	Evaluation of Two Strategies for Community-Based Safety Monitoring during Seasonal Malaria Chemoprevention Campaigns in Senegal, Compared with the National Spontaneous Reporting System. <i>Pharmaceutical Medicine</i> , <b>2018</b> , 32, 189-200	2.3	3
66	An international qualitative study exploring patients' experiences of cutaneous leishmaniasis: study set-up and protocol. <i>BMJ Open</i> , <b>2018</b> , 8, e021372	3	3
65	Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006141	4.8	21
64	Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006837	4.8	8
63	High-level artemisinin-resistance with quinine co-resistance emerges in <i>P. falciparum</i> malaria under in vivo artesunate pressure. <i>BMC Medicine</i> , <b>2018</b> , 16, 181	11.4	11
62	Malaria pigment stimulates chemokine production by human microvascular endothelium. <i>Acta Tropica</i> , <b>2017</b> , 172, 125-131	3.2	8
61	Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of <i>Leishmania</i> in the Indian Subcontinent. <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e0005190	4.8	20
60	Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	8
59	Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 443	4	7
58	Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. <i>Parasites and Vectors</i> , <b>2017</b> , 10, 47	4	39
57	Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e0005781	4.8	18
56	Systematic review of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiasis and the case for data-sharing. <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e0006053	4.8	9

55	Implications of Plasmodium vivax Biology for Control, Elimination, and Research. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2016</b> , 95, 4-14	3.2	37
54	Trial design for evaluating novel treatments during an outbreak of an infectious disease. <i>Clinical Trials</i> , <b>2016</b> , 13, 31-8	2.2	15
53	New approaches to measuring anthelmintic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel. <i>Parasites and Vectors</i> , <b>2016</b> , 9, 41	4	25
52	Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1001997	11.6	116
51	The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD). <i>PLoS Neglected Tropical Diseases</i> , <b>2016</b> , 10, e0004784	4.8	14
50	Experimental Treatment of Ebola Virus Disease with Brincidofovir. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162199	3.7	59
49	Toward Measuring Schistosoma Response to Praziquantel Treatment with Appropriate Descriptors of Egg Excretion. <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e0003821	4.8	25
48	Strength of recommendations in WHO guidelines using GRADE was associated with uptake in national policy. <i>Journal of Clinical Epidemiology</i> , <b>2015</b> , 68, 703-7	5.7	22
47	Evaluating clinical trial designs for investigational treatments of Ebola virus disease. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001815	11.6	39
46	A changing model for developing health products for poverty-related infectious diseases. <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e3379	4.8	7
45	Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 868-76	5.1	12
44	First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea. <i>Infection, Genetics and Evolution</i> , <b>2015</b> , 33, 314-9	4.5	14
43	Global health security: the wider lessons from the west African Ebola virus disease epidemic. <i>Lancet, The</i> , <b>2015</b> , 385, 1884-901	40	296
42	Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4046-52	5.9	31
41	Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas. <i>International Journal of Pharmaceutics</i> , <b>2014</b> , 468, 55-63	6.5	0
40	Randomised controlled trials for Ebola: practical and ethical issues. <i>Lancet, The</i> , <b>2014</b> , 384, 1423-4	40	115
39	Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009. <i>Malaria Journal</i> , <b>2014</b> , 13, 114	3.6	19
38	Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e3286	4.8	89

37	A four-month gatifloxacin-containing regimen for treating tuberculosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1588-98	59.2	271
36	Open source clinical science for emerging infections. <i>Lancet Infectious Diseases</i> , <b>2014</b> , 14, 8-9	25.5	58
35	Pharmaceutical development and optimization of azithromycin suppository for paediatric use. <i>International Journal of Pharmaceutics</i> , <b>2013</b> , 441, 218-26	6.5	19
34	The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. <i>The Lancet Global Health</i> , <b>2013</b> , 1, e371-9	13.6	187
33	Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , <b>2013</b> , 7, e2130	4.8	73
32	Practical dosing of praziquantel for schistosomiasis in preschool-aged children. <i>Tropical Medicine and International Health</i> , <b>2013</b> , 18, 1085-1089	2.3	14
31	Potential drug development candidates for human soil-transmitted helminthiases. <i>PLoS Neglected Tropical Diseases</i> , <b>2011</b> , 5, e1138	4.8	62
30	Standardised versus actual white cell counts in estimating thick film parasitaemia in African children under five. <i>Tropical Medicine and International Health</i> , <b>2011</b> , 16, 551-4	2.3	11
29	Simultaneous Determination of Artemether and Azithromycin in Suppositories by Reversed Phase HPLC. <i>Analytical Letters</i> , <b>2011</b> , 44, 2732-2743	2.2	8
28	Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2011</b> , 85, 619-25	3.2	29
27	Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2011</b> , 84, 543-50	3.2	40
26	Alternative visual displays of metaanalysis of malaria treatment trials to facilitate translation of research into policy. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2010</b> , 68, 422-31	2.9	2
25	Epidemiology and control of human gastrointestinal parasites in children. <i>Expert Review of Anti-Infective Therapy</i> , <b>2010</b> , 8, 219-34	5.5	157
24	Drug combinations for visceral leishmaniasis. <i>Current Opinion in Infectious Diseases</i> , <b>2010</b> , 23, 595-602	5.4	42
23	Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 809-21	2.8	38
22	Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. <i>Tropical Medicine and International Health</i> , <b>2009</b> , 14, 918-25	2.3	42
21	Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. <i>Tropical Medicine and International Health</i> , <b>2008</b> , 13, 83-90	2.3	16
20	Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. <i>Malaria Journal</i> , <b>2008</b> , 7, 234	3.6	18

19	Editorial commentary: mortality associated with severe Plasmodium falciparum malaria increases with age. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 158-60	11.6	37
18	Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 733-40	2.9	119
17	Chemotherapy in the treatment and control of leishmaniasis. <i>Advances in Parasitology</i> , <b>2006</b> , 61, 223-74	3.2	166
16	Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. <i>Lancet Infectious Diseases</i> , <b>2005</b> , 5, 763-74	25.5	161
15	Drug resistance hampers our capacity to roll back malaria. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41 Suppl 4, S247-57	11.6	48
14	Antimalarial compounds: from bench to bedside. <i>Journal of Experimental Biology</i> , <b>2003</b> , 206, 3753-9	3	95
13	Developments in the treatment of leishmaniasis and trypanosomiasis. <i>Expert Opinion on Emerging Drugs</i> , <b>2002</b> , 7, 61-7	3.7	12
12	Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. <i>Lancet Infectious Diseases</i> , <b>2002</b> , 2, 494-501	25.5	578
11	Pharmacokinetics of artesunate after single oral administration to rats. <i>BMC Pharmacology</i> , <b>2001</b> , 1, 12		24
10	Controlling malaria: challenges and solutions. <i>Tropical Medicine and International Health</i> , <b>2001</b> , 6, 922-7	2.3	24
9	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. <i>SSRN Electronic Journal</i> ,	1	40
8	Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study		1
7	ISARIC Clinical Data Report issued: 14 July 2021		13
6	Early clinical characteristics of Covid-19: scoping review		1
5	Development and validation of the 4C Deterioration model for adults hospitalised with COVID-19		6
4	Characterising long term Covid-19: a living systematic review		29
3	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol		7
2	Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study		8



- 1 Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study